Health Condition 1: L988- Other specified disorders of the skin and subcutaneous tissue
Conditions
Interventions
Intervention1: 92% Lactic Acid Peel + Oral Tranexamic Acid: Patients will receive 92% lactic acid chemical peel applied to facial melasma lesions at 3-week intervals for a total of 6 sessions, along w
Sponsors
Dr Pdiangty Giri Mawlong
Eligibility
Inclusion criteria
Inclusion criteria: Patients of either sex of age more than 18 years and less than 50 years, with melasma of epidermal variety with melasma areas and severity index score more than 10 who had not taken treatment for melasma for the last 4 weeks were included in the study.
Exclusion criteria
Exclusion criteria: Pregnant or lactating women. Patients with known hypersensitivity to lactic acid, glycolic acid, or tranexamic acid. Patients with history of liver disease or hepatitis B/C infection. Patients with active bacterial, viral, or fungal skin infection on the face. Patients with history of keloid or hypertrophic scar formation. Women taking oral contraceptive pills or hormone replacement therapy. Patients with severe systemic illness or malignancy. Presence of active dermatoses on the face such as atopic dermatitis, eczema, or seborrheic dermatitis. Patients currently using oral or topical retinoids. Patients taking anticoagulants or drugs affecting coagulation (e.g., warfarin, aspirin, NSAIDs). Patients with history of thromboembolic disorders including deep venous thrombosis (DVT). Patients with history of photosensitivity disorders. Patients with history of adverse effects related to tranexamic acid such as abdominal bloating, headache, tinnitus, or menstrual irregularities. Patients unwilling to comply with follow-up or expecting complete cure without maintenance therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Melasma Area and Severity Index (MASI) score from baseline between the two treatment groups.Timepoint: Baseline (Week 0) Week 3 Week 6 Week 9 Week 12 Week 15 Week 18 (End of treatment) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in Melasma Quality of Life (MELASQOL) score To assess improvement in melasma-related quality of life following treatment. Clinical photographic assessment of pigmentation improvement Standardized digital facial photographs to document clinical response.Timepoint: For Melasqol Baseline (Week 0) Week 18 (End of treatment) For photographic assessment Baseline Week 3 Week 6 Week 9 Week 12 Week 15 Week 18 | — |
Countries
India
Contacts
Public ContactDr Pdiangty Giri Mawlong
Government Medical College, Haldwani
Outcome results
None listed